X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
gastroenterology & hepatology (36) 36
humans (27) 27
female (26) 26
index medicus (26) 26
male (26) 26
middle aged (26) 26
hepatitis (23) 23
interferon (23) 23
aged (22) 22
hepatitis c virus (22) 22
hepatitis c (21) 21
genetic aspects (18) 18
hepatocellular carcinoma (18) 18
patients (18) 18
adult (17) 17
analysis (17) 17
ribavirin (17) 17
health aspects (16) 16
hepatology (16) 16
hepatitis c, chronic - drug therapy (15) 15
treatment outcome (15) 15
antiviral agents - therapeutic use (14) 14
drug therapy, combination (14) 14
genotype (14) 14
hepacivirus - genetics (14) 14
gastroenterology (13) 13
aged, 80 and over (12) 12
antiviral agents - administration & dosage (12) 12
chronic hepatitis c (12) 12
liver (12) 12
colorectal surgery (11) 11
genotype & phenotype (11) 11
japan (11) 11
liver cirrhosis (11) 11
medicine & public health (11) 11
pegylated interferon (11) 11
abdominal surgery (10) 10
care and treatment (10) 10
genotypes (10) 10
liver cancer (10) 10
medical research (10) 10
medicine, experimental (10) 10
surgical oncology (10) 10
efficacy (9) 9
hepatitis c, chronic - virology (9) 9
hepatoma (9) 9
infections (9) 9
risk (9) 9
biological response modifiers (8) 8
cirrhosis (8) 8
hepatocellular-carcinoma (8) 8
multivariate analysis (8) 8
prognosis (8) 8
safety (8) 8
telaprevir (8) 8
combination therapy (7) 7
daclatasvir plus asunaprevir (7) 7
hcv (7) 7
hemodialysis (7) 7
sorafenib (7) 7
sustained virologic response (7) 7
virus-infection (7) 7
disease (6) 6
drug therapy (6) 6
fibrosis (6) 6
il28b (6) 6
imidazoles - administration & dosage (6) 6
interferon therapy (6) 6
interferon-alpha - therapeutic use (6) 6
isoquinolines - administration & dosage (6) 6
management (6) 6
ribavirin - therapeutic use (6) 6
risk factors (6) 6
sulfonamides - administration & dosage (6) 6
therapy (6) 6
time factors (6) 6
young adult (6) 6
antiviral agents (5) 5
asunaprevir (5) 5
chronic hcv infection (5) 5
daclatasvir (5) 5
dialysis patients (5) 5
drug administration schedule (5) 5
genetic-variation (5) 5
hepacivirus - isolation & purification (5) 5
imidazoles - therapeutic use (5) 5
peginterferon (5) 5
polyethylene glycols - therapeutic use (5) 5
recombinant proteins - therapeutic use (5) 5
rna, viral - blood (5) 5
sustained response (5) 5
virology (5) 5
virus diseases (5) 5
albumin-bilirubin grade (4) 4
antigens (4) 4
antiviral agents - adverse effects (4) 4
association (4) 4
chronic hepatitis (4) 4
chronic hepatitis-c (4) 4
chronic infection (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Annals of Oncology, ISSN 0923-7534, 11/2016, Volume 27, Issue suppl_7
Journal Article
Journal of Gastroenterology, ISSN 0944-1174, 3/2017, Volume 52, Issue 3, pp. 385 - 395
DCV-TRIO, a fixed-dose combination of daclatasvir (pangenotypic NS5A inhibitor), asunaprevir (NS3/4A protease inhibitor), and beclabuvir (non-nucleoside NS5B... 
Medicine & Public Health | NS5B inhibitor | Colorectal Surgery | Hepatology | Direct-acting antiviral | Gastroenterology | Abdominal Surgery | NS5A inhibitor | HCV therapy | Surgical Oncology | NS3/4A inhibitor | PEGINTERFERON/RIBAVIRIN | CHRONIC HEPATITIS-C | SIMEPREVIR | DACLATASVIR PLUS ASUNAPREVIR | RIBAVIRIN | PHASE-3 TRIAL | DOUBLE-BLIND | INTERFERON-ALPHA 2A | GASTROENTEROLOGY & HEPATOLOGY | TREATMENT-NAIVE PATIENTS | Isoquinolines - adverse effects | Benzazepines - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Imidazoles - administration & dosage | Male | RNA, Viral - blood | Hepatitis C, Chronic - complications | Indoles - administration & dosage | Aged, 80 and over | Adult | Female | Imidazoles - therapeutic use | Hepacivirus - isolation & purification | Double-Blind Method | Drug Administration Schedule | Antiviral Agents - therapeutic use | Imidazoles - adverse effects | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Indoles - adverse effects | Liver Cirrhosis - virology | Sulfonamides - therapeutic use | Benzazepines - therapeutic use | Antiviral Agents - adverse effects | Isoquinolines - therapeutic use | Sulfonamides - adverse effects | Indoles - therapeutic use | Aged | Benzazepines - administration & dosage | Sustained Virologic Response | Isoquinolines - administration & dosage | Drug Combinations | Sulfonamides - administration & dosage | Protease inhibitors | Proteases | Dosage and administration | Genetic aspects | Drug therapy, Combination | Biological response modifiers | Hepatitis C virus | Health aspects | Liver cirrhosis
Journal Article
Journal of Gastroenterology, ISSN 0944-1174, 1/2018, Volume 53, Issue 1, pp. 119 - 128
Hepatitis C virus (HCV) infection is common in hemodialysis patients and worsens their prognosis, while antiviral therapy options are limited. Recently,... 
DAAs | Medicine & Public Health | Colorectal Surgery | Hemodialysis | Hepatology | Gastroenterology | Abdominal Surgery | HCV | Surgical Oncology | CKD | KIDNEY-DISEASE | METAANALYSIS | EFFICACY | SAFETY | COMBINATION | PLUS ASUNAPREVIR | THERAPY | DIALYSIS PATIENTS | GENOTYPE 1 INFECTION | GASTROENTEROLOGY & HEPATOLOGY | STAGE RENAL-DISEASE | Isoquinolines - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Imidazoles - administration & dosage | Male | Isoquinolines - pharmacology | Aged, 80 and over | Adult | Female | Retrospective Studies | Drug Therapy, Combination | Antiviral Agents - pharmacology | Imidazoles - adverse effects | Japan | Genotype | Treatment Outcome | Imidazoles - pharmacology | Hepatitis C, Chronic - drug therapy | Sulfonamides - pharmacology | Antiviral Agents - administration & dosage | Antiviral Agents - adverse effects | Sulfonamides - adverse effects | Aged | Sustained Virologic Response | Isoquinolines - administration & dosage | Sulfonamides - administration & dosage | Renal Dialysis | Virus diseases | Medical research | Analysis | Medicine, Experimental | Hepatitis C virus | Health aspects | Alanine | Liver | Exanthema | Transaminase | Clinical trials | Data processing | Hepatocellular carcinoma | Infections | Genotype & phenotype | Hepatitis | Fibrosis | Alanine transaminase | Hepatitis C | Kidney transplantation
Journal Article
Journal of Gastroenterology, ISSN 0944-1174, 1/2017, Volume 52, Issue 1, pp. 94 - 103
Journal Article
Journal of Gastroenterology, ISSN 0944-1174, 2/2018, Volume 53, Issue 2, pp. 247 - 257
This prospective cohort study searched for factors associated with a response to nucleos(t)ide analogue/peg-interferon (NUC/peg-IFN) sequential therapy.A total... 
Covalently closed circular DNA | Hepatitis B core-related antigen | Hepatitis B surface antigen | Medicine & Public Health | Anti-viral therapy | Colorectal Surgery | Hepatology | Chronic hepatitis | Gastroenterology | Abdominal Surgery | Surgical Oncology | CLOSED CIRCULAR DNA | MANAGEMENT | SUSTAINED RESPONSE | CORE-RELATED ANTIGEN | HBSAG | LAMIVUDINE | HEPATOCELLULAR-CARCINOMA | PEGINTERFERON ALPHA-2A | VIRUS INFECTION | GASTROENTEROLOGY & HEPATOLOGY | HBV INFECTION | Recombinant Proteins - therapeutic use | Prospective Studies | Humans | Middle Aged | Male | Drug Monitoring - methods | Polyethylene Glycols - therapeutic use | Hepatitis B Surface Antigens - blood | Adenine - therapeutic use | Aged, 80 and over | Adult | Female | Drug Therapy, Combination | Hepatitis B Core Antigens - blood | Adenine - analogs & derivatives | Drug Administration Schedule | Organophosphonates - therapeutic use | Antiviral Agents - therapeutic use | Interferon-alpha - therapeutic use | Biomarkers - blood | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Hepatitis B, Chronic - virology | Interferon-alpha - administration & dosage | Hepatitis B, Chronic - drug therapy | Aged | Antigens | Hepatitis | Adefovir | Polyethylene glycol | Adefovir dipivoxil | Interferon
Journal Article
Hepatology, ISSN 0270-9139, 02/2018, Volume 67, Issue 2, pp. 505 - 513
Glecaprevir (nonstructural protein 3/4A protease inhibitor) and pibrentasvir (nonstructural protein 5A inhibitor) (G/P), a coformulated once‐daily, all oral,... 
ASIA | SOFOSBUVIR | CIRRHOSIS | PHASE-3 TRIAL | PREVALENCE | RIBAVIRIN | GASTROENTEROLOGY & HEPATOLOGY | BURDEN | Cirrhosis | Antiretroviral drugs | Hepatitis | Chronic infection | Infections | Interferon | Safety | Hepatitis C | Patients | Ribavirin | Genotypes | Original
Journal Article
Journal of Gastroenterology, ISSN 0944-1174, 11/2014, Volume 49, Issue 11, pp. 1485 - 1494
Journal Article
Journal Article
Journal of Gastroenterology and Hepatology, ISSN 0815-9319, 09/2017, Volume 32, Issue 9, pp. 1611 - 1616
Journal Article